References
- Sommi, R. W.; Crismon, M. L.; Bowden, C. L. Fluoxetine: A Serotonin‐Specific, Second‐Generation Antidepressant. Pharmacotherapy. 1987, 7, 1–14. DOI: 10.1002/j.1875-9114.1987.tb03496.x.
- Thompson, C.; Peveler, R. C.; Stephenson, D.; McKendrick, J. Compliance with Antidepressant Medication in the Treatment of Major Depressive Disorder in Primary Care: A Randomized Comparison of Fluoxetine and a Tricyclic Antidepressant. Am. J. Psychiatry. 2000, 157, 338–343. DOI: 10.1176/appi.ajp.157.3.338.
- Gobin, V.; De Bock, M.; Broeckx, B. J. G.; Kiselinova, M.; De Spiegelaere, W.; Vandekerckhove, L.; Van Steendam, K.; Leybaert, L.; Deforce, D. Fluoxetine Suppresses Calcium Signaling in Human T Lymphocytes through Depletion of Intracellular Calcium Stores. Cell Calcium. 2015, 58, 254–263. DOI: 10.1016/j.ceca.2015.06.003.
- Brodnanova, M.; Hatokova, Z.; Evinova, A.; Cibulka, M.; Racay, P. Differential Impact of Imipramine on Thapsigargin-and Tunicamycin-Induced Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Neuroblastoma SH-SY5Y Cells. Eur. J. Pharmacol. 2021, 902, 174073. DOI: 10.1016/j.ejphar.2021.174073.
- Di Rosso, M. E.; Sterle, H. A.; Cremaschi, G. A.; Genaro, A. M. Beneficial Effect of Fluoxetine and Sertraline on Chronic Stress-Induced Tumor Growth and Cell Dissemination in a Mouse Model of Lymphoma: Crucial Role of Antitumor Immunity. Front. Immunol. 2018, 9, 1341. DOI: 10.3389/fimmu.2018.01341.
- Dey, S.; Bajaj, S. O. Promising Anticancer Drug Thapsigargin: A Perspective toward the Total Synthesis. p. Synth. Commun. 2018, 48, 1–13. DOI: 10.1080/00397911.2017.1386789.
- Manganaro, R.; Zonsics, B.; Bauer, L.; Lorenzo Lopez, M.; Donselaar, T.; Zwaagstra, M.; Saporito, F.; Ferla, S.; Strating, J. R. P. M.; Coutard, B.; et al. Synthesis and Antiviral Effect of Novel Fluoxetine Analogues as Enterovirus 2C Inhibitors. Antiviral. Res. 2020, 178, 104781. DOI: 10.1016/j.antiviral.2020.104781.
- Bauer, L.; Manganaro, R.; Zonsics, B.; Hurdiss, D. L.; Zwaagstra, M.; Donselaar, T.; Welter, N. G. E.; van Kleef, R. G. D. M.; Lopez, M. L.; Bevilacqua, F.; et al. Rational Design of Highly Potent Broad-Spectrum Enterovirus Inhibitors Targeting the Nonstructural Protein 2C. PLOS Biol. 2020, 18, e3000904. DOI: 10.1371/journal.pbio.3000904.
- Avorn, J. Learning about the Safety of Drugs—A Half-Century of Evolution. N Engl. J. Med. 2011, 365, 2151–2153. DOI: 10.1056/NEJMp1110327.
- Asherson, R. A.; et al. Multiple Autoimmune Diseases in a Young Woman: Tuberculosis and Splenectomy as Possible Triggering Factors? Another Example of the “Mosaic” of Autoimmunity. J. Rheumatol. 2008, 35, 1224–1227.
- Bascones-Martinez, A.; Mattila, R.; Gomez-Font, R.; Meurman, J. H. Immunomodulatory Drugs: Oral and Systemic Adverse Effects. Med. Oral Patol. Oral Cir. Bucal. 2014, 19, e24–e31. DOI: 10.4317/medoral.19087.
- Sayeed, I. B.; Lakshma Nayak, V.; Shareef, M. A.; Chouhan, N. K.; Kamal, A. Design, Synthesis and Biological Evaluation of Imidazopyridine-Propenone Conjugates as Potent Tubulin Inhibitors. Medchemcomm. 2017, 8, 1000–1006. 10.1039/c7md00043j.30108815.
- Taler, M.; Gil-Ad, I.; Lomnitski, L.; Korov, I.; Baharav, E.; Bar, M.; Zolokov, A.; Weizman, A. Immunomodulatory Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) on Human T Lymphocyte Function and Gene Expression. Eur. Neuropsychopharmacol. 2007, 17, 774–780. DOI: 10.1016/j.euroneuro.2007.03.010.
- Schiepers, O. J.; Wichers, M. C.; Maes, M. Cytokines and Major Depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005, 29, 201–217. DOI: 10.1016/j.pnpbp.2004.11.003.
- Wong, D. T.; Perry, K. W.; Bymaster, F. P. The Discovery of Fluoxetine Hydrochloride (Prozac). Nat. Rev. Drug Discov. 2005, 4, 764–774. DOI: 10.1038/nrd1821.
- Garrison, G. D.; Levin, G. M. Factors Affecting Prescribing of the Newer Antidepressants. Ann. Pharmacother. 2000, 34, 10–14. DOI: 10.1345/aph.19079.
- Montgomery, S. Efficacy and Safety of the Selective Serotonin Reuptake Inhibitors in Treating Depression in Elderly Patients. Int. Clin. Psychopharmacol. 1998, 13, S49–S54.
- Wilde, M. I.; Benfield, P. Fluoxetine. Pharmacoeconomics. 1998, 13, 543–561. DOI: 10.2165/00019053-199813050-00007.
- Vardanyan, R.; Hruby, V. Chapter 31-Antibacterial Drugs. Synth Best-Seller Drugs. 2016, 645–667.
- García-García, M. L.; Tovilla-Zárate, C. A.; Villar-Soto, M.; Juárez-Rojop, I. E.; González-Castro, T. B.; Genis-Mendoza, A. D.; Ramos-Méndez, M. Á.; López-Nárvaez, M. L.; Saucedo-Osti, A. S.; Ruiz-Quiñones, J. A.; et al. Fluoxetine Modulates the Pro-Inflammatory Process of IL-6, IL-1β and TNF-α Levels in Individuals with Depression: A Systematic Review and Meta-Analysis. Psychiatry Res. 2022, 307, 114317. DOI: 10.1016/j.psychres.2021.114317.
- Kubera, M.; et al. Anti-Inflammatory Effects of Antidepressants through Suppression of the Interferon-γ/Interleukin-10 Production Ratio. J. Clin. Psychopharmacol. 2001, 21, 199–206.
- Roumestan, C.; Michel, A.; Bichon, F.; Portet, K.; Detoc, M.; Henriquet, C.; Jaffuel, D.; Mathieu, M. Anti-Inflammatory Properties of Desipramine and Fluoxetine. Respir. Res. 2007, 8, 1–11. DOI: 10.1186/1465-9921-8-35.
- Maes, M. The Immunoregulatory Effects of Antidepressants. Hum. Psychopharmacol. Clin. Exp. 2001, 16, 95–103. DOI: 10.1002/hup.191.
- Catanzaro, M.; Corsini, E.; Rosini, M.; Racchi, M.; Lanni, C. Immunomodulators Inspired by Nature: A Review on Curcumin and Echinacea. Molecules. 2018, 23, 2778. DOI: 10.3390/molecules23112778.
- Chouhan, N. K.; Ananthabhat, S. K.; Vaidya, S.; Srihari, P. A Scalable Process for the Synthesis of Key Intermediates Novoldiamine & Hydroxynovaldiamine and Their Utility in Chloroquine, Hydroxychloroquine and Mepacrine Synthesis. Synth. Commun. 2022, 52, 1004–1011. 10.1080/00397911.2022.2061358.
- Edgar, V. A.; Sterin-Borda, L.; Cremaschi, G. A.; Genaro, A. M. Role of Protein Kinase C and cAMP in Fluoxetine Effects on Human T-Cell Proliferation. Eur. J. Pharmacol. 1999, 372, 65–73.
- Cashman, J. R.; Voelker, T.; Johnson, R.; Janowsky, A. Stereoselective Inhibition of Serotonin Re-Uptake and Phosphodiesterase by Dual Inhibitors as Potential Agents for Depression. Bioorg. Med. Chem. 2009, 17, 337–343. DOI: 10.1016/j.bmc.2008.10.065.
- Sant, S.; Poulin, S.; Hildgen, P. Effect of Polymer Architecture on Surface Properties, Plasma Protein Adsorption, and Cellular Interactions of Pegylated Nanoparticles. J. Biomed. Mat. Res. Part A. 2008, 87, 885–895.
- Ray, A.; Dittel, B. N. Isolation of Mouse Peritoneal Cavity Cells. J. Vis. Exp. 2010, 28, 1488.
- Wilson, N. S.; Yang, B.; Morelli, A. B.; Koernig, S.; Yang, A.; Loeser, S.; Airey, D.; Provan, L.; Hass, P.; Braley, H.; et al. ISCOMATRIX Vaccines Mediate CD8+ T‐Cell Cross‐Priming by a MyD88‐Dependent Signaling Pathway. Immunol. Cell Biol. 2012, 90, 540–552. DOI: 10.1038/icb.2011.71.
- Haase, D.; Puan, K. J.; Starke, M.; Lai, T. S.; Soh, M. Y. L.; Karunanithi, I.; San Luis, B.; Poh, T. Y.; Yusof, N.; Yeap, C. H.; et al. Large-Scale Isolation of Highly Pure “Untouched” Regulatory T Cells in a GMP Environment for Adoptive Cell Therapy. J. Immunother. 2015, 38, 250–258. DOI: 10.1097/CJI.0000000000000083.
- Lyons, A. B.; S. J.; Blake, K. V.; Doherty, 9. p Flow Cytometric Analysis of Cell Division by Dilution of CFSE and Related Dyes. CP. Cytometry. 2013, 64, 1–9.11.12. DOI: 10.1002/0471142956.cy0911s64.